Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Autologous platelet lysate for treatment of refractory ocular GVHD

Bone Marrow Transplantation volume 47, pages 1558–1563 (2012)Cite this article

Subjects

Abstract

Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II–IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmer’s test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as ‘responders’ when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

    Article  CAS  Google Scholar 

  2. Balaram M, Rashid S, Dana R . Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf 2005; 3: 203–211.

    Article  Google Scholar 

  3. Westeneng AC, Hettinga Y, Lokhorst H, Verdonck L, van Dorp S, Rothova A . Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea 2010; 29: 758–763.

    Article  Google Scholar 

  4. Uchino M, Ogawa Y, Uchino Y, Mori T, Okamoto S, Tsubota K . Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. Br J Ophthalmol 2011; 96: 34–37.

    Article  Google Scholar 

  5. Riemens A, te Boome L, Imhof S, Kuball J, Rothova A . Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol 2010; 21: 485–494.

    Article  Google Scholar 

  6. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  7. Khanal S, Tomlinson A . Tear physiology in dry eye associated with chronic GvHD. Bone Marrow Transplant 2012; 47: 115–119.

    Article  CAS  Google Scholar 

  8. Tabbara KF, Al-Ghamdi A, Al-Mohareb F, Ayas M, Chaudhri N, Al-Sharif F et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology 2009; 116: 1624–1629.

    Article  Google Scholar 

  9. Wang Y, Ogawa Y, Dogru M, Tatematsu Y, Uchino M, Kamoi M et al. Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. Bone Marrow Transplant 2009; 45: 1077–1083.

    Article  Google Scholar 

  10. Doughty MJ, Glavin S . Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 2009; 29: 573–583.

    Article  Google Scholar 

  11. Lelli GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI . Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25: 635–638.

    Article  Google Scholar 

  12. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE . Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27: 459–461.

    Article  CAS  Google Scholar 

  13. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br J Ophthalmol 1999; 83: 390–395.

    Article  CAS  Google Scholar 

  14. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA . GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000; 25: 1101–1103.

    Article  CAS  Google Scholar 

  15. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579–583.

    Article  CAS  Google Scholar 

  16. Chiang CC, Lin JM, Chen WL, Tsai YY . Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 2007; 26: 861–863.

    Article  Google Scholar 

  17. van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J . Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol 1989; 227: 184–187.

    Article  CAS  Google Scholar 

  18. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT . Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4–15.

    Article  CAS  Google Scholar 

  19. Martinez-Zapata MJ, Marti-Carvajal A, Sola I, Bolibar I, Angel Exposito J, Rodriguez L et al. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. Transfusion 2009; 49: 44–56.

    Article  Google Scholar 

  20. Sandri G, Bonferoni MC, Rossi S, Ferrari F, Mori M, Del Fante C et al. Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions. J Pharm Pharmacol 2010; 63: 189–198.

    Article  Google Scholar 

  21. Del Fante C, Perotti C, Bonferoni MC, Rossi S, Sandri G, Ferrari F et al. Platelet lysate mucoadhesive formulation to treat oral mucositis in graft versus host disease patients: a new therapeutic approach. AAPS PharmSciTech 2011; 12: 893–899.

    Article  CAS  Google Scholar 

  22. Hartwig D, Harloff S, Liu L, Schlenke P, Wedel T, Geerling G . Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects? Transfusion 2004; 44: 1724–1731.

    Article  CAS  Google Scholar 

  23. Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 153–162.

  24. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25: 900–907.

    Article  Google Scholar 

  25. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL . Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000; 118: 615–621.

    Article  CAS  Google Scholar 

  26. Rossi GCM, Pasinetti GM, Scudeller L, Milano G, Mazzone A, Raimondi M et al. The Italian version of the Glaucoma Symptom Scale questionnaire: translation, validation and reliability. J Glaucoma, 21: (in press; manuscript number JOG-D-10-00291R2).

  27. Lee BL, Gutierrez P, Gordon M, Wilson MR, Cioffi GA, Ritch R et al. The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol 1998; 116: 861–866.

    Article  CAS  Google Scholar 

  28. Bron AJ, Evans VE, Smith JA . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640–650.

    Article  Google Scholar 

  29. Bachmann B, Taylor RS, Cursiefen C . The association between corneal neovascularization and visual acuity: a systematic review. Acta Ophthalmol (doi:10.1111/j.1755-3768.2011.02312.x).

    Article  Google Scholar 

  30. Dell S, Peters S, Muther P, Kociok N, Joussen AM . The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 1928–1937.

    Article  Google Scholar 

  31. Yu FS, Yin J, Xu K, Huang J . Growth factors and corneal epithelial wound healing. Brain Res Bull 2010; 81: 229–235.

    Article  CAS  Google Scholar 

  32. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S . Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000; 19: 113–129.

    Article  CAS  Google Scholar 

  33. Wilson SE, Mohan RR, Mohan RR, Ambròsio R, Hong J, Lee J . The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001; 20: 625–637.

    Article  CAS  Google Scholar 

  34. Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A . Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res 2007; 39: 124–129.

    Article  Google Scholar 

  35. Alio JL, Pastor S, Ruiz-Colecha J, Rodriguez A, Artola A . Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J Refract Surg 2007; 23: 617–619.

    Article  Google Scholar 

  36. Lopez-Plandolit S, Morales MC, Freire V, Etxebarria J, Duran JA . Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 2010; 29: 843–848.

    Article  Google Scholar 

  37. Geremicca W, Fonte C, Vecchio S . Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms. Blood Transfus 2010; 8: 107–112.

    PubMed  PubMed Central  Google Scholar 

  38. Lopez-Plandolit S, Morales MC, Freire V, Grau AE, Duran JA . Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea 2011; 30: 1312–1317.

    Article  Google Scholar 

  39. Eppley BL, Woodell JE, Higgins J . Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502–1508.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Eye Clinic of Pavia, IRCCS Policlinico S Matteo Foundation, Pavia, Italy

    S Pezzotta & E R Antoniazzi

  2. Immunohaematology and Trasfusion Service, Apheresis Unit, IRCCS Policlinico S Matteo Foundation, Pavia, Italy

    C Del Fante, M Cervio & C Perotti

  3. Scientific Direction, IRCCS Policlinico S Matteo Foundation, Pavia, Italy

    L Scudeller

Authors
  1. S Pezzotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Del Fante
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Scudeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Cervio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E R Antoniazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Perotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Pezzotta.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pezzotta, S., Fante, C., Scudeller, L. et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant 47, 1558–1563 (2012). https://doi.org/10.1038/bmt.2012.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.64

Keywords

This article is cited by

Search

Advanced search

Quick links